<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01539850</url>
  </required_header>
  <id_info>
    <org_study_id>CS-006</org_study_id>
    <nct_id>NCT01539850</nct_id>
  </id_info>
  <brief_title>Safety Evaluation of the LGL102 in Obese Subjects Treated With OMS102</brief_title>
  <official_title>Safety Evaluation of the LGL102 in Obese Subjects Treated With OMS102. A Prospective Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IntraPace, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IntraPace, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the LGL102 implant safety in obese to
      morbidly obese subjects treated with OMS102 system. The effect of the therapy on body weight
      changes will be also evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transgastric sensor site healing</measure>
    <time_frame>3 months</time_frame>
    <description>Food sensor transgastric site healing will be evaluated during a gastro endoscopy exam performed three months after implant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Excess weight loss</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Percentage of excess body weight loss (%EWL) compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Evaluation</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Occurrence and severity of all adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Evaluation of the quality of life using the Moorehead-Ardelt II questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eating Behavior</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Eating behavior (cognitive restraint, uncontrolled eating, and emotional eating) using the Three Factor Eating Questionnaire (TFEQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comorbid Conditions</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Any reduction of blood pressure and oral diabetes medications</description>
  </secondary_outcome>
  <enrollment type="Actual">34</enrollment>
  <condition>Obesity</condition>
  <condition>Morbid Obesity</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OMS102</intervention_name>
    <description>Subjects will receive implanted OMS102 System.</description>
    <other_name>abiliti System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 18 - 60 years old at time of screening

          -  BMI of 35 to 55 at time of screening

          -  History of obesity ≥ 5 years

          -  The subject has been under routine care of the investigator or another single
             physician that can supply a medical record for at least 6 months prior to enrollment

          -  Women with childbearing potential (i.e., not post-menopausal or surgically sterilized)
             must agree to use adequate birth control methods

          -  No significant weight loss (&lt; 5%) within four months prior to enrollment as documented
             in the subject's medical record.

          -  Successful psychological evaluation following the institution psychological evaluation
             protocol for bariatric surgery or successful historic assessment performed no more
             than 6 months prior to enrollment.

          -  Glycosylated Hemoglobin; HbA1c ≤ 7.0 % at Visit 2 or historic value performed no more
             than 3 months prior to enrollment.

          -  If taking anti-depressant medications, they must be stable for at least six months
             prior to enrollment

          -  Willingness to refrain from using prescription, over the counter or herbal weight loss
             products for the duration of the trial

          -  Alert, mentally competent, and able to understand and willing to comply with the
             requirements of the clinical trial, and personally motivated to abide by the
             requirements and restrictions of the clinical trial

          -  Able to provide voluntary informed consent

        Exclusion Criteria:

          -  Any prior bariatric surgery

          -  Other implanted electrical stimulation devices (e.g. pacemaker, defibrillator,
             neurostimulator)

          -  Diagnosed with past or current psychiatric condition that may impair his/her ability
             to comply with the study procedures

          -  Use of anti-psychotic medications

          -  Diagnosed with a eating disorder such as bulimia or binge eating

          -  Obesity due to an endocrinopathy (e.g. Cushing disease)

          -  Insulin therapy

          -  GI disease such as hiatal hernia (&gt; 5cm), gastroparesis, esophageal motility disorders
             or intractable constipation.

          -  Any history of peptic ulcer disease within 5 years prior to enrollment

          -  History of Barrett's esophagus

          -  Women who are pregnant, lactating or anticipate becoming pregnant within 24 months

          -  Arthritis or other pathologies limiting physical activities that physician feels
             should exclude the patient from the study.

          -  Cardiac history that physician feels should exclude the patient from the study.

          -  Use of another investigational device or agent in the 30 days prior to enrollment

          -  A history of life-threatening disease within 5 years prior to enrollment

          -  Any other condition that, in the opinion of the investigator, would make the subject
             unsuitable for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Horbach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stadtkrankenhaus Schwabach</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wolfart Klinik</name>
      <address>
        <city>Graefelfing</city>
        <zip>92166</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stadtkrankenhaus Schwabach</name>
      <address>
        <city>Schwabach</city>
        <zip>91126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chirurgische Klinik und Poliklinik I Zentrum für Operative Medizin</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2012</study_first_submitted>
  <study_first_submitted_qc>February 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2012</study_first_posted>
  <last_update_submitted>February 27, 2012</last_update_submitted>
  <last_update_submitted_qc>February 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>gastric stimulation</keyword>
  <keyword>morbid obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

